KR850007378A - 인터로이킨-2의 안정화 조성물의 제조방법 - Google Patents

인터로이킨-2의 안정화 조성물의 제조방법 Download PDF

Info

Publication number
KR850007378A
KR850007378A KR1019850002345A KR850002345A KR850007378A KR 850007378 A KR850007378 A KR 850007378A KR 1019850002345 A KR1019850002345 A KR 1019850002345A KR 850002345 A KR850002345 A KR 850002345A KR 850007378 A KR850007378 A KR 850007378A
Authority
KR
South Korea
Prior art keywords
composition
interleukin
reducing compound
acid
aqueous solution
Prior art date
Application number
KR1019850002345A
Other languages
English (en)
Other versions
KR920005048B1 (ko
Inventor
야스시 미꾸라 (외 2)
Original Assignee
구라바야시 이꾸시로
다께다 야꾸힝 고오교 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP59071568A external-priority patent/JPS60215631A/ja
Priority claimed from JP60013226A external-priority patent/JPS60222424A/ja
Priority claimed from JP60037184A external-priority patent/JPS61197527A/ja
Application filed by 구라바야시 이꾸시로, 다께다 야꾸힝 고오교 가부시끼 가이샤 filed Critical 구라바야시 이꾸시로
Publication of KR850007378A publication Critical patent/KR850007378A/ko
Application granted granted Critical
Publication of KR920005048B1 publication Critical patent/KR920005048B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

인터로이킨-2의 안정화 조성물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (25)

  1. 인터로이킨-2 수용액에 인체혈청 알부민, 환원 화합물 또는 그둘 모두를 첨가하고, 그 용액의 pH를 3~6이 되도록 조절함을 특징으로 하는 인체혈청 알부민, 환원 화합물 또는 그들 모두를 함유하고 pH~6을 나타내도록 조절된 용액상의 인터로이킨-2 조성물의 제조방법.
  2. 제1항에 있어서, 인터로이킨-2가 인체 인터로이킨-2인 방법.
  3. 제1 또는 2항에 있어서, 인터로이킨-2가 재조합 인터로이킨-2인 방법.
  4. 제2항에 있어서, 인체 인터로이킨-2가 비글리코실화된 인체 인터로이킨-2인 방법.
  5. 제1항에 있어서, 인터로인킨-2가 20,000~80,000 활성단위/mg의 비활성을 갖는 방법.
  6. 제1항에 있어서, 인터로인킨-2가 수용액상으로서 1~80,000 활성단위/ml의 농도인 방법.
  7. 제1항에 있어서, 조성물이 염을 포함하지 않는 방법.
  8. 제1항에 있어서, 조성물이 인체혈청알부민을 함유하는 방법.
  9. 제8항에 있어서, 인체혈청 알부민의 수용액상으로서 0.1~50mg/ml의 농도인 방법.
  10. 제1항에 있어서, 조성물이 환원 화합물을 함유하는 방법.
  11. 제10항에 있어서, 환원 화합물이 산성 환원화합물인 방법.
  12. 제11항에 있어서, 산성환원 화합물이 글루타치온, 티옥트산, N-아세틸시스테인, 1~7 탄소원자의 티오알카논산 또는 아스코르브산인 방법.
  13. 제10항에 있어서, 환원 화합물이 수용액상으로서 0.05~20mg/ml의 농도인 방법.
  14. 제1항에 있어서, 조성물이 인체혈청 알부민 및 환원 화합물을 동시에 함유하는 방법.
  15. 제1항에 있어서, 조성물이 모노아미노 지방족아미노산, 고리족 아미노산, 단당류, 당알코올 또는 이들을 병행하여 더 함유하는 방법.
  16. 제1항에 있어서, 조성물이 모노아미노 지방족 아미노산을 더 함유하는 방법.
  17. 제16항에 있어서, 모노아미노 지방족 아미노산이 수용액상으로서 5~50mg/ml의 농도인 방법.
  18. 제1항에 있어서, 조성물의 pH가 3~5.5인 방법.
  19. 제1항에 있어서, 조성물이 수용액, 동결물, 또는 동결건조물의 형태인 방법.
  20. 제1항에 있어서, 조성물이 동결건조물의 형태인 방법.
  21. 제1항에 있어서, 동결된 조성물을 얻기위해 생성된 용액을 더 동결시키는 방법.
  22. 제1항에 있어서, 동결건조된 조성물을 얻기위해 생성된 용액을 더 동결건조시키는 방법.
  23. 제1항에 있어서, 수용액을 산성환원 화합물, 산성 아미노산, 무기산 또는 완충용액 또는 유기산을 이용하여 조절하는 방법.
  24. 제23항에 있어서, 수용액을 무기산으로 조절하는 방법.
  25. 제23항에 있어서, 수용액을 산성환원 화합물로 조절하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850002345A 1984-04-09 1985-04-08 인터로이킨-2의 안정화 조성물 제조방법 KR920005048B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP59071568A JPS60215631A (ja) 1984-04-09 1984-04-09 インタ−ロイキン−２組成物
JP71568 1984-04-09
JP71568/1984 1984-04-09
JP13226/1985 1985-01-25
JP60013226A JPS60222424A (ja) 1985-01-25 1985-01-25 インタ−ロイキン−２組成物
JP60037184A JPS61197527A (ja) 1985-02-25 1985-02-25 インタ−ロイキン−２組成物
JP37184/1985 1985-02-25

Publications (2)

Publication Number Publication Date
KR850007378A true KR850007378A (ko) 1985-12-04
KR920005048B1 KR920005048B1 (ko) 1992-06-26

Family

ID=27280163

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850002345A KR920005048B1 (ko) 1984-04-09 1985-04-08 인터로이킨-2의 안정화 조성물 제조방법

Country Status (13)

Country Link
US (2) US4645830A (ko)
EP (1) EP0158487B1 (ko)
KR (1) KR920005048B1 (ko)
AU (1) AU579359B2 (ko)
CA (1) CA1285478C (ko)
DE (1) DE3583880D1 (ko)
DK (1) DK148885A (ko)
ES (1) ES8603271A1 (ko)
IE (1) IE58161B1 (ko)
IL (1) IL74823A (ko)
NZ (1) NZ211702A (ko)
PH (1) PH22897A (ko)
PT (1) PT80247B (ko)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US5702699A (en) * 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
AU598300B2 (en) * 1986-09-04 1990-06-21 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4938956A (en) * 1987-04-01 1990-07-03 International Minerals & Chemical Corp. Synergistic immunostimulating composition and method
CA1339757C (en) * 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
FR2639232A1 (fr) * 1988-10-21 1990-05-25 Sanofi Sa Medicaments contenant une interleukine-2 glycosylee
US5417970A (en) * 1988-10-21 1995-05-23 Sanofi Drugs containing a glycosylated interleukin-2
WO1990006127A1 (en) * 1988-12-06 1990-06-14 Otsuka Pharmaceutical Co., Ltd. STABILIZED COMPOSITION OF INTERLEUKIN-1$g(b)
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
WO1990007340A1 (en) * 1989-01-09 1990-07-12 Meiji Milk Products Co., Ltd. Anti-hiv agent
DE3900649A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
CA1339070C (en) * 1989-01-26 1997-07-29 Wulf Droge Treatment of diseases associated with cysteine deficiency
IT1240314B (it) * 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5140010A (en) * 1989-09-28 1992-08-18 Immunobiology Research Institute Stabilized aqueous formulations of thymopentin
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5580577A (en) * 1990-01-11 1996-12-03 Herzenberg; Leonard A. Method of treating the symptoms of human rhinovirus infection
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
WO1992009623A1 (fr) * 1990-11-23 1992-06-11 Roussel-Uclaf PROCEDE DE PREPARATION D'UNE PROTEINE COMPORTANT AU MOINS UN PONT DISULFURE INTRAMOLECULAIRE PAR OXYDATION, A UN pH INFERIEUR A 5,0, DE LA PROTEINE RECOMBINANTE REDUITE CORRESPONDANTE
ES2143457T3 (es) * 1991-03-19 2000-05-16 Huntsman International Trading Procedimiento para la fabricacion de masas espumadas basadas en elastomeros de poliurea.
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
WO1995002411A1 (en) * 1993-07-16 1995-01-26 Mallinckrodt Veterinary Limited Stabilised polypeptide growth factor formulation at low ph
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
WO1999055310A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
EP1220682B1 (en) * 1999-10-04 2006-11-22 Novartis Vaccines and Diagnostics, Inc. Stabilized liquid polypeptide-containing pharmaceutical compositions
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
AU781678C (en) 1999-11-18 2005-12-22 Ischemix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
EP1401862A4 (en) * 2001-05-17 2004-12-15 Ceremedix Inc PEPTIDE COMPOUNDS AGAINST OXYGENIC SUBSTANCES AND FREE RADICALS
DE10159245A1 (de) * 2001-12-03 2003-06-18 Degussa Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
SI1599222T1 (sl) 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
WO2007147590A2 (en) * 2006-06-22 2007-12-27 Gambro, Inc. Solution and method to reduce, treat and/or prevent oxidative stress and cell activation
RU2739078C2 (ru) 2010-04-27 2020-12-21 ЭсСиАйЭл Текнолоджи ГмбХ Стабильные водные композиции белка MIA/CD-RAP
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
EP3889178A1 (en) 2013-08-30 2021-10-06 Takeda GmbH Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
WO2019074886A1 (en) 2017-10-09 2019-04-18 Terumo Bct Biotechnologies, Llc LYOPHILIZATION CONTAINER AND METHOD OF USE
US11609043B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
IL294388A (en) 2020-01-14 2022-08-01 Synthekine Inc il2 orthologs and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) * 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4404280A (en) * 1981-07-16 1983-09-13 Steven Gillis Process for preparing murine interleukin 2 in the presence of interleukin 1 from an interleukin 2 nonproducer malignant cell line and cell line therefor
DE3149360A1 (de) * 1981-12-12 1983-06-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt "verfahren zur reinigung und/oder phytohaemagglutinin-abtrennung von human-interleukin-2"
HU189251B (en) * 1982-04-07 1986-06-30 Asahi Kasei Kogyo Kk,Jp Process for stabilizing tumor necrosis factor
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4490289A (en) * 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4578335A (en) * 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins

Also Published As

Publication number Publication date
DK148885D0 (da) 1985-04-02
CA1285478C (en) 1991-07-02
DK148885A (da) 1985-10-10
KR920005048B1 (ko) 1992-06-26
AU579359B2 (en) 1988-11-24
DE3583880D1 (de) 1991-10-02
NZ211702A (en) 1988-11-29
EP0158487A2 (en) 1985-10-16
IE850902L (en) 1985-10-09
ES542028A0 (es) 1985-12-16
US4645830A (en) 1987-02-24
IL74823A (en) 1989-07-31
AU4083985A (en) 1985-10-17
IL74823A0 (en) 1985-07-31
EP0158487B1 (en) 1991-08-28
US4812557A (en) 1989-03-14
IE58161B1 (en) 1993-07-28
ES8603271A1 (es) 1985-12-16
PT80247B (pt) 1987-10-20
EP0158487A3 (en) 1987-08-19
PT80247A (en) 1985-05-01
PH22897A (en) 1989-01-19

Similar Documents

Publication Publication Date Title
KR850007378A (ko) 인터로이킨-2의 안정화 조성물의 제조방법
KR850005455A (ko) r-인터페론 안정화 조성물의 제조방법
KR860003019A (ko) 안정한 에리트로포에틴 제제의 제조방법
CA2035893A1 (en) Stable preparation containing motilins
KR880004819A (ko) 펩티드 제제
US5563122A (en) Stabilized parathyroid hormone composition
JPS6440433A (en) Aqueous liquid composition of thrombin
INOUE et al. Studies on ATP Citrate Lyase of Rat Liver I. Purification and Some Properties
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
KR860002268A (ko) 피장(避腸)영양액의 제조방법
Kahlenberg et al. Reconstitution of D‐glucose transport in vesicles composed of lipids and intrinsic protein (Zone 4.5) of the human erythrocyte membrane
CA2254145A1 (en) Improved process to stabilize proteins
JPS54147916A (en) Preparation of urokinase injection
PT93744A (pt) Processo para a preparacao de formulacoes liofilizadas de peptidios, nomeadamente, de timopentina
KR920011516A (ko) 약제학적 조성물
GB1527972A (en) Stabilized glucose isomerase enzyme concentrate and process for preparing the same
KR900004799B1 (ko) 안정한 감마 인터페론 제제 및 이의 제조방법
KR840002657A (ko) 인터페론 조성물의 제조방법
KR850003162A (ko) 인체 γ-인터페론 단량체의 제조방법
AU4065393A (en) Pharmaceutical compositions containing IL-6
KR880002507A (ko) 페닐퀴놀린 카복실산의 동결건조 약제 조성물
Tallan et al. Homolanthionine synthesis by human liver cystathionase
GB1526205A (en) Treatment of interferon-like material
KR860000869A (ko) γ-인터페론 안정화 조성물의 제조방법
DK164023C (da) Fremgangsmaade til fremstilling af gammaglobulin, der er egnet til intravenoes indgivelse

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee